Pimobendan Increases Survival of Cardiomyopathic Hamsters

Autor: Meel, Jacques C. A. van, Mauz, Annerose B. M., Wienen, Wolfgang, Diederen, Willi
Zdroj: Journal of Cardiovascular Pharmacology; March 1989, Vol. 13 Issue: 3 p508-508, 1p
Abstrakt: Summary: We investigated the effect of the new cardiotonic drug pimobendan on survival of hereditary cardiomyopathic hamsters. Untreated cardiomyopathic hamsters served as controls. A 50 mortality was observed after 280 days for the control group and after 318 days for the pimobendan-treated animals. After 340 days, survival was 0 for the untreated cardiomyopathic hamsters and 27 in the pimobendan-treated group. We conclude that pimobendan slows the progression of heart failure in cardiomyopathic hamsters.
Databáze: Supplemental Index